Please ensure Javascript is enabled for purposes of website accessibility

Amid the Coronavirus Frenzy, Novavax Remains a Risky Bet

By Prosper Junior Bakiny - Updated Mar 6, 2020 at 3:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite its attempt to develop a vaccine for COVID-19, Novavax's prospects aren't particularly attractive.

The COVID-19 outbreak continues to get worse. More than 70 countries have now seen confirmed cases of the disease. In the U.S., more than a dozen states have had confirmed cases of COVID-19, and more than 10 people have died from it. While many still believe the outbreak is manageable, others are increasingly worried that it will turn into a full-blown pandemic. Amid this frenzy, several biotech companies are looking to develop a vaccine for the SARS-CoV-2 virus, which is the virus that causes the illness COVID-19.

Obviously, the company that manages to develop a vaccine for this potentially deadly virus successfully could reap immense financial benefits. Novavax (NVAX 11.12%) -- a clinical-stage vaccine company headquartered in Maryland -- is currently perceived as one of the leaders in the race to come up with a vaccine for the SARS-CoV-2 virus. But despite its attempt to prevent a global pandemic, Novavax remains a risky play.

Hand holding test tube of blood labeled Coronavirus testing

Image source: Getty Images.

Where Novavax stands in the race to develop a vaccine for COVID-19

On Feb. 26, Novavax announced that it was making progress in its attempt to develop a vaccine for COVID-19. More precisely, the company said it was "assessing multiple nanoparticle vaccine candidates in animal models prior to identifying an optimal candidate for human testing." Novavax was able to develop a vaccine rapidly because it had prior experience dealing with other strands of coronavirus, according to its CEO Stanley C. Erck.

Novavax said it was planning on starting the testing phase for its potential vaccine in the spring. Shares of Novavax soared on the news that the company was relatively close to starting clinical trials, indicating that investors had high hopes for the vaccine. 

The field is crowded

Of course, Novavax is by no means the only company looking to develop a vaccine (or a treatment) for COVID-19, nor is it the frontrunner in this race. That title arguably goes to Gilead Sciences (GILD 0.89%) whose product -- remdesivir -- was crowned as the most promising potential treatment for COVID-19 by officials at the World Health Organization (WHO). On Feb. 26, Gilead Sciences announced it had initiated two phase 3 clinical studies to investigate the efficacy of remdesivir as a potential treatment for COVID-19.

Elsewhere, Moderna (MRNA 4.97%) made quick work of developing a vaccine for COVID-19, and the company announced on Feb. 24 that its potential vaccine for the disease -- mRNA-1273 -- had been shipped to the National Institute of Allergy and Infectious Diseases (NIAID) to start a phase 1 study.

Other companies are also looking to develop vaccines for COVID-19, and investors looking to place their bets on whichever company is the most likely to come out a winner are going back and forth between all of these companies, rendering their stocks volatile. On March 3, shares of Moderna and Novavax sank on the news that Inovio Pharmaceuticals (INO 9.25%) was looking to begin clinical trials for its potential vaccine for COVID-19 in April.

Novavax's pipeline

Other than its attempts to find a vaccine for COVID-19, Novavax boasts several interesting products in its pipeline. Most notably, the company recently submitted a potential vaccine for the flu -- dubbed NanoFlu -- to the U.S. Food and Drug Administration (FDA) for review. NanoFlu was developed primarily for adults over the age of 65. The FDA granted NanoFlu the "fast track" designation, which expedites the review process for drugs that fill an "unmet medical need."

Novavax's pipeline also boasts other potential vaccines for the flu, as well as a potential vaccine for Ebola.

A risky play

There are two major reasons why investing in Novavax at this point is risky. First, even assuming that the company manages to develop a vaccine for COVID-19 successfully, it probably won't be the first -- or even the only -- company to accomplish such a feat. Other biotech companies are further ahead in their attempts to prevent a COVID-19 pandemic, and betting that Novavax will come out a winner in this race is wishful thinking, at best. Sure, it could happen, but it isn't likely given what we know so far.

Second, Novavax currently has no approved products on the market, and while its NanoFlu vaccine seems promising -- and will likely receive the green light from the FDA -- this success would hardly make the company's prospects particularly enticing. While investors should keep on monitoring Novavax, there are far more promising biotech stocks to consider buying. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.15 (11.12%) $5.72
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.36 (0.89%) $0.55
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.89 (9.25%) $0.16
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.